Abeona Therapeutics Receives FDA Orphan Drug Designation For EB-101 Gene Therapy Product For Patients With … – Clinical Leader
|
Abeona Therapeutics Receives FDA Orphan Drug Designation For EB-101 Gene Therapy Product For Patients With …
Clinical Leader New York And Cleveland, (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA … |
